Objectives: Plasminogen activator inhibitor-1 (PAI-1) is a major anti-fibrinolytic glycoprotein thought to promote vascular diseases. Recently we have shown that systemically injecting mice with kainate, an analog of the principal brain excitatory neurotransmitter glutamate, immediately induced PAI-1 mRNA in brain vascular cells which are not known to contain glutamate receptors. Here we further investigated whether: (a) kainate also increases PAI-1 gene expression in the cardiac vascular bed; (b) subunits of kainate /AMPA receptors could be expressed in cardiac and brain vascular cells; and (c) PAI-1 mRNA could be similarly induced by agonists of adrenergic receptors that are candidates to act downstream in kainate-activated pathways. Methods: We analyzed cardiac and brain cryosections for 35 PAI-1 mRNA, as well as mRNAs encoding three receptor subunits, by in situ hybridization using S-labeled specific riboprobes. PAI-1 activity was tested in cardiac homogenates using one-phase reverse zymography. Results: Prominent PAI-1 mRNA hybridization signals were induced in the vascular cells of the heart, and unexpectedly, also in cardiocytes, within 1-2 h after injection of kainate (i.p., 11-25 mg / kg body weight); the signals persisted for at least 8 h and disappeared after 24 h. In addition, PAI-1 activity increased (|5 fold) 2-10 h after the treatment. In contrast, mRNAs encoding the kainate /AMPA receptor subunits could not be detected. The adrenergic agents adrenaline (3.5 mg / kg) and isoproterenol (200 mg / kg) exerted kainate-like effects in cardiovascular cells. Conclusions: These results revealed, for the first time, that PAI-1 gene expression can be enhanced locally in the cardiovascular system by a fast-acting neurological mechanism triggered by glutamate receptors, whose pathway and relation to catecholamines, which exerted similar effects, have yet to be resolved. These findings raised the possibility that excessive glutamate, or stress-related catecholamines, may increase the risk of stroke and myocardial infarction.
Introduction
serine proteases specifically convert inactive plasminogen into active plasmin, the ultimate fibrinolytic enzyme. Plasminogen activator inhibitor-1 (PAI-1) is an inducPlasmin is a non-specific trypsin-like protease that is also ible, secreted |50-kDa glycoprotein of the serpin superinvolved in tissue extracellular proteolysis (reviewed in family (reviewed in Refs. [1] [2] [3] ). PAI-1 is considered the Refs. [4] [5] [6] ). In addition, components of the PA system principal physiological inhibitor of tissue-type (tPA) and (specifically PAI-1, uPA and its specific surface receptor urokinase-type (uPA) plasminogen activators (PAs). These uPAR) can modulate cell adhesion and migration in a proteolytic-independent manner [7] . In accordance with these multiple functions, the PA system has been impli-Increased concentration of plasma PAI-1 has been cells can be enhanced through a neurotransmitter. Howassociated with an increased risk for thrombotic diseases in ever, it was not clear whether PAI-1 induction in brain humans, in particular myocardial infarction [3, 13, 14] and vascular cells occurred independently of neighbouring stroke [14, 15] . Furthermore, the levels of PAI-1 antigen or neuronal cells, or rather, was mediated through kainatetranscripts in the vascular wall, which are low in healthy induced effectors released from these neuronal cells. individuals, were elevated in endothelial and smooth Furthermore, because the vascular induction was detected muscle cells of atherosclerotic plaques [16] [17] [18] [19] , suggesting after systemically injecting kainate, it was of interest to test that PAI-1 may play a role in atherogenesis as well, whether it occurred exclusively in the brain or also perhaps by promoting matrix deposition and thrombotic emcompassed the vascular bed of other organs. complications associated with plaque rupture. Studies
Here we report that kainate intravenously injected into using rodent models, including transgenic and gene-demice immediately induced PAI-1 mRNA in cardiac vascuficient mice, have confirmed that PAI-1 can promote lar cells and, unexpectedly, also in cardiocytes, and it also vascular thrombosis [20, 21] , but conversely, could not increased PAI-1 activity in cardiac homogenates. In addidetect any PAI-1 gene influence on atherosclerotic plaques tion, because adrenoceptors are candidates to act down- [22] . Yet, other studies have indicated that PAI-1 could stream in kainate-activated pathways, we also tested the inhibit neointimal thickening [9] , and furthermore, it could effect on PAI-1 gene expression in the heart and brain of protect against cardiac rupture, a uPA-dependent event that adrenoreceptor agonists (i.e. adrenaline, an a-and bfollows myocardial infarction [10] .
adrenoceptor agonist, and isoproterenol, a non-selective PAI-1 gene expression could be modulated by a large b-adrenoceptor agonist). Our results show that neurologigroup of hormones, growth factors, cytokines and incal and / or neuroendocrine mechanisms can enhance PAI-1 flammatory agents in diverse cell types in vitro [1] .
gene expression in the murine cardiovascular system in Notably, bacterial endotoxins administered into mice elevivo. vated PAI-1 mRNA in the kidney and liver specifically in endothelial cells [23, 24] . So far, only a few studies have reported on PAI-1 expression in cardiac cells. For example, 2. Methods transforming growth factor-b (TGF-b) activated the PAI-1 gene promoter in cultured chicken embryonic cardiac cells 2.1. Treatment of mice [25] , and angiostatin II enhanced PAI-1 expression in fibroblasts derived from human hearts [26] . Still, very little FVB / N female mice (n542), 3-4 months old, propis known about the physiological mechanisms controlling agated and maintained as previously described [31] , were PAI-1 gene expression in cardiovascular cells in vivo.
injected i.p. with the following solutions: (i) PBS (250 ml, Specifically, it is yet unknown whether neurological or serving as control); (ii) kainate (a freshly prepared solution neuroendocrine mechanisms are involved in this control.
in PBS, at the indicated amount; Sigma); (iii) adrenaline Previously we have studied the response of the PAI-1 (3.5 mg / kg body weight; Teva Pharmaceutical Industries, gene in the brain to kainate [27] , a potent excitatory and Israel); (iv) isoproterenol (200 mg / kg; Abbot, Chicago, excitotoxic compound which is a glutamate analog. Gluta-USA). At the indicated times after treatment, mice were mate is the most prevalent excitatory neurotransmitter in heavily anesthetized with ether. Their organs were immethe central nervous system (CNS) [28, 29] , whose indiately removed and frozen over dry ice and kept frozen at volvement in the autonomic nervous system (ANS) is 2708C for up to 4 weeks. The investigation conforms with poorly understood. In rodents, kainate causes extensive the Guide for the Care and Use of Laboratory Animals brain toxicity which involves activation of early and late published by the US National Institute of Health (NIH) genes (see Ref. [27] for a detailed list of references). These publication no. 85-23, revised 1996. effects are thought to be mediated by kainate interaction with two subclasses of glutamate receptors, the kainate and 2.2. In situ hybridization AMPA subclasses named after their preferred agonist. Within the complex family of glutamate receptors, the Thin cryosections (12 mm) were prepared from hearts kainate /AMPA receptors comprise the non-NMDA ionotand brains and tested through in situ hybridization exactly 35 ropic receptors that act as ligand-gated ion channels and as we have previously described [27, 32] , using S-labeled are highly prevalent in the CNS (reviewed in Refs. [28-riboprobes at the antisense or sense orientations, specific 30]). We have previously found, through in situ mRNA for PAI-1 [27] or for the kainate receptor subunits GluR1, hybridization experiments, that kainate systemically inGluR3, and GluR5 (plasmids carrying GluR sequences jected into mice, caused a rapid and robust induction of were a kind gift from Professor V. Teichberg). Sections PAI-1 mRNA in brain nerve cells, and also, unexpectedly, were maintained under photographic emulsion for 2-3 in brain blood vessel cells [27] [27] . Briefly, samples in cardiocytes were applied to mini SDS-PAGE gels containing purified human plasminogen and casein. After electrophoresis, the To test whether kainate could induce PAI-1 mRNA in SDS was washed out with Triton X-100 and the gels were cardiac vascular cells, we injected the drug i.p. into mice at incubated for proteolysis with human uPA (0.5 IU / ml, several doses in the range of 8-25 mg / kg body weight. American Diagnostica) for 4 h. Consequently, the uPA Cardiac cryosections were tested for PAI-1 mRNA through 35 converted the plasminogen throughout the gels into plasin situ hybridization using PAI-1-specific S-labeled min, which in turn degraded the casein. Next, the gels were riboprobes at the antisense and sense orientations. Hybridistained with Coomassie brilliant blue. On the lightly zation signals were induced in vascular cells in the heart stained background, PAI-1 yielded dark bands resulting within 1-2 h after injecting kainate, and persisted for at from inhibition of casein degradation. Parallel control gels least 6-8 h (Fig. 1B,C ,G,H) as previously reported for were treated similarly, but they did not include casein; they vascular cells in the brain [27] . Signals returned to the served as a control to assure that the dark bands in the basal level after 1 day. The signals were detected with the casein-containing gels did not result from just staining of antisense but not with the sense riboprobe ( Fig. 1D ), sample proteins. Results were quantitated using the Bioindicating PAI-1 mRNA specificity. Induction was ob- tained at kainate concentrations of 11 mg / kg body weight test this issue here, because it is not firmly established and or higher, with signals increasing in a dose-dependent our results raised a major question concerning the localizamanner. No PAI-1 mRNA induction was noted at nontion of the effective receptors. To date, several subunits of convulsive concentrations of 10 mg / kg and lower. As in the kainate /AMPA receptors are known, designated the brain, PAI-1 mRNA hybridization signals in cardiac GluR1-GluR7, K1 and K2, and assembled together in vessels were associated with smooth muscle cells (Fig. homomeric or heteromultimeric complexes [28] [29] [30] . Like 1H). Signals were also seen in endothelial cells as judged all glutamate receptors, the kainate /AMPA receptors are by morphological appearance.
abundant in the CNS, however they show different disInterestingly, PAI-1 mRNA was also detected in cartribution patterns. These receptors could possibly account diocytes, including cells containing elongated nuclei typifor the previously reported robust PAI-1 mRNA induction cal of cardiomyocytes (Fig. 1B,C,E,F) (Fig. 1B) . After 6 h, hybridization 3Aa). In contrast, GluR1 mRNA or GluR3 mRNA hybridisignals were more abundant in cells residing in the upper zation signals were missing in brain vascular cells, while region of the ventricular myocardium and septum, whereas seen in neuronal cells (Figs. 2B and 3Bb), in agreement they were usually missing in the atria (Fig. 1C ). Somewith previous results [34] . Additionally, no GluR1 or times, the transition was sharp between areas densely GluR3 mRNAs could be detected in the heart (Figs. 2C packed with cells containing signals, and adjacent areas and 3Cc). Similarly, hybridization signals could not be where such cells were rare (see Fig. 1E for an example).
detected in the heart and in brain blood vessels after Interestingly, blood vessels containing strong hybridization hybridization with the GluR5 riboprobe, or with all three signals were also localized in areas where the surrounding GluR riboprobes in spinal cord sections (results not cardiocytes were devoid of signals, especially in the lower shown). These results suggest that at least the three kainate parts of the cardiac muscle (Fig. 1C) . Notably, signals receptor subunits tested here are not expressed in murine were also associated with cells in the endocardium. cardiovascular cells at appreciable levels. Homogenate samples were analyzed along with conditioned medium collected from the murine hepatic carcinoma Hepa 1c17, previously shown to secrete high PAI-1 activity after treatment with the phorbol ester PMA [33] . The Hepa PAI-1 inhibitory activity is seen in the gel as a dark band corresponding to an |50-kDa protein (Fig. 5,  lanes 1 and 10) . Only marginal bands of PAI-1 activity could be detected in cardiac homogenates of control mice (lanes 2 and 3), while this band increased considerably 3 and 6 h after treatment with kainate (lanes 4 and 5), adrenaline (lanes 6 and 7) or isoproterenol (lanes 8 and 9). Densitometer scanning conducted for three mice for each drug indicated elevations of PAI-1 activity of 5.460.4, 4.061.4 and 4.761.6 (fold6S.E.) 6 h after treatment with kainate, adrenaline or isoproterenol, respectively.
Testing brain and cardiac sections for mRNAs

Discussion
The findings that a glutamate analog and adrenergic agents can rapidly increase PAI-1 mRNA in cardiovascular cells have indicated, for the first time, that PAI-1 gene expression can be controlled in the cardiovascular system through neurological and / or neuroendocrine mechanisms. We do not yet know what is the anatomical localization residing in brain centers controlling the peripheral auof the glutamate receptors that communicate with cartonomic nervous system (ANS) or neuroendocrine pathdiovascular target cells for PAI-1 induction, and through ways. In these routes, adrenergic or cholinergic receptors which pathway they transmit their effect. In principle, act in downstream target cells [35] . Accordingly, we tested these glutamate receptors could reside in brain or spinal whether PAI-1 mRNA could be induced after systemic cord areas controlling or mediating ANS sympathetic and administration of adrenaline and isoproterenol. As seen in parasympathetic transmission or neuroendocrine pathways Fig. 4 , both agonists induced PAI-1 mRNA immediately (i.e. the hypothalamic-pituitary-adrenal axis) [35] [36] [37] . and strongly in vascular cells of the heart (A,C) or brain Interestingly, very little is known about the role of (D,G) as well as in cardiocytes (B,F). Signals persisted for glutamate in the ANS and neuroendocrine pathways. at least 6 h post treatment; however, at that time they Recently it has been demonstrated that microinjection of somewhat declined in the vascular cells, an effect not glutamate, kainate or NMDA into specific spinal cord or observed after kainate treatment.
hypothalamic sites elicited, within minutes, changes in arterial blood pressure, heart rate, and myocardial contrac-3.4. Kainate and adrenergic agents induced PAI-1 tibility [38] [39] [40] , and also increased plasma catecholamines activity in cardiac homogenates [39] . However, the influence on gene expression has not been tested in these cases. As far as we know, our results We used one-phase reverse zymography to test whether on the PAI-1 gene provide the first evidence that glutamate PAI-1 activity was also elevated after injecting the drugs.
can also promote gene expression in ANS-innervated Homogenates were prepared from hearts excised from tissues, specifically the cardiovascular system. perfused animals at different times after drug injection.
The ANS and neuroendocrine pathways involve adren- ergic or cholinergic receptors located downstream in the nothing is known at the level of gene expression. Thus, surface membrane of the target cardiovascular cells themcatecholamines were previously shown to rapidly increase selves [35] . However, the knowledge of the in vivo effects the plasma levels of tPA (but not of PAI-1) through of circulating stress-related catecholeamines on the fibb-adrenoceptors [41, 42] . This effect, however, was attriburinolytic system is still limited, and furthermore, virtually ted to the increased release of pre-existing tPA from 5) ; adrenaline (lanes 6 and 7) or isoproterenol (lanes 8 and 9). Mice were sacrificed 3 or 6 h after the treatment, as indicated in the figure. Gel A contained plasminogen and casein, as substrates for uPA and plasmin, respectively. Gel B did not contain any substrate, serving as a control.
endothelial pools and decreased clearance in the liver, could stabilize the extracellular environment, while excess rather than to enhanced gene expression. Our results have PAI-1 could disturb the proteolytic balance in the extracelshown, for the first time, that catecholamines, and thus the lular milieu, thereby interfering with cell-matrix and cellneuroendocrine mechanism, can affect the fibrinolytic cell interactions. On the other hand, excessive PAI-1 could capacity in cardiovascular tissues at the level of PAI-1 act more efficiently to prevent cardiac rupture after gene expression. Our results, however, are not sufficiently myocardial infarction, as has recently been learned through complete to indicate whether catecholamines are also PAI-1 and uPA-deficient mice [10] . involved in mediating the kainate effect on PAI-1 gene. To
As previously mentioned, our study has provided the resolve the kainate-mediated pathway a comprehensive first indication that glutamate can rapidly elevate gene pharmacological study should be undertaken.
expression in cardiovascular cells. The PAI-1 gene is It is noteworthy that kainate, being a glutamate structurusually activated by biological effectors of pleiotropic al analog, can also inhibit glutamate transport through influences, i.e. they lead simultaneously to the activation of excitatory amino acid transporters (EAATs) [43] . Such several genes, rather than exclusively the PAI-1 gene. We inhibition may result in extracellular increase of glutamate, therefore assume that the PAI-1 gene is only one repreand, if occurring in cardiac neuronal elements in the heart, sentative of a group of genes that can be induced in vivo in could in principle lead to PAI-1 induction in adjacent cells cardiovascular cells through kainate /AMPA receptors. carrying any subclass of active glutamate receptors. At Thus, our findings raise the possibility that cardiovascular present, however, it is not known if such receptors are homeostasis may be regulated, in part, through a fast, found in vascular smooth muscle cells and cardiocytes.
long-lasting neurological mechanism affecting gene exFurthermore, we found that NMDA, an agonist of the pression. It would be interesting to search for such putative NMDA receptor subclass, did not induce PAI-1 mRNA in genes. cardiocytes (unpublished results), thus excluding this reIn summary, our findings revealed that glutamate, or ceptor subclass as a primary or secondary mediator of adrenergic agents, can induce PAI-1 mRNA in car-PAI-1 induction. diovascular cells and can elevate PAI-activity locally in the Interestingly, after kainate treatment we did not detect in heart. These findings indicate that neurological or neuroenvascular or cardiac cells an induction of the mRNA docrine mechanisms, or both, can control cardiovascular encoding plasminogen activator inhibitor-2 (PAI-2) (the PAI-1 gene expression, and suggest that excessive glutasecond PA-specific inhibitor), uPA mRNA and activity, or mate or catecholamines may increase the risk of cartPA activity (unpublished results). These differences from diovascular diseases, in particular myocardial infarction PAI-1 indicate some specificity of the kainate /AMPA and stroke. receptors regarding the capacity to induce in cardiovascular cells PAI-1, among the fibrinolytic components. Likewise, the adrenergic agents did not induce uPA mRNA, or
